SCHEMBL6656495

SCHEMBL6656495

CCc1cccc(CCBr)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.52
TP53 P04637 1/20 0.44
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MGLL Q99685 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2A6 P11509 1/20 0.40
DRD2 P14416 2/20 0.39
DRD3 P35462 2/20 0.39
DRD1 P21728 1/20 0.39
DRD4 P21917 1/20 0.39
DRD5 P21918 1/20 0.39
TAAR1 Q96RJ0 4/20 0.38
BCL2 P10415 1/20 0.38
RAPGEF4 Q8WZA2 1/20 0.38
IDO1 P14902 1/20 0.37
TRPA1 O75762 1/20 0.37
NISCH Q9Y2I1 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31573996 1.00 TDP1 (0.52) TDP1TP53MEN1KMT2AMGLL
SCHEMBL4427688 0.88 TDP1 (0.65) TDP1MEN1KMT2ACYP1A2DRD2
SCHEMBL80925 0.87 TP53 (0.41) TDP1TP53MEN1KMT2AMGLL
SCHEMBL9490025 0.85 TP53 (0.52) TP53MEN1KMT2AMGLLCYP1A2
SCHEMBL166894 0.83 TP53 (0.61) TP53MGLLCYP1A2CYP2A6BCL2
SCHEMBL1403956 0.81 TRPA1 (0.48) TP53MGLLCYP1A2CYP2A6BCL2
SCHEMBL31455995 0.81 TP53 (0.48) TP53MEN1KMT2AMGLLCYP1A2
SCHEMBL589019 0.81 TP53 (0.48) TP53MEN1KMT2AMGLLCYP1A2
SCHEMBL30152326 0.81 TRPA1 (0.48) TP53MGLLCYP1A2CYP2A6BCL2
SCHEMBL28204549 0.81 TDP1 (0.56) TDP1MEN1KMT2ACYP1A2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024145659-A1 HETEROCYCLE FUSED GAMMA-CARBOLINES ACTING ON THE SEROTONINE 5-HT2A RECEPTOR INTRA-CELLULAR THERAPIES, INC. (US) 2024-07-04 WO disclosed
EP-1077940-B1 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES PFIZER (US) 2004-07-14 EP disclosed
US-6610711-B2 4-phenylpiperidines for the treatment of pruritic dermatoses PFIZER INC. 2003-08-26 US disclosed
US-20030078282-A1 Novel 4-phenylpiperidines for the treatment of pruritic dermatoses PFIZER INC. 2003-04-24 US disclosed
EP-1077940-A1 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES PFIZER INC. (US) 2001-02-28 EP disclosed
WO-1999059971-A1 NOVEL 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES PFIZER INC. (US) 1999-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078282-A1 Novel 4-phenylpiperidines for the treatment of pruritic dermatoses HRH2, HRH4, HRH1 TDP1 2293/4885TP53 4781/4885MEN1 4700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.